KCT0002166
Completed
N/A
A Clinical Trial to Evaluate the Changes of Blood flow in Arterial anastomosis of Free flap after the Intraoperative administration of Alprostadil (Eglandin®) using Duplex ultrasonography in Patients who undergoing Free flap transfer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Diseases of the skin and subcutaneous tissue
- Sponsor
- Asan Medical Center
- Enrollment
- 44
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Plan to recieve free flap transfer under general anesthesia
- •2\. Age: \>\=18 and \<80 years old
- •3\. Administration of alprostadil during surgery
- •4\. Volunteer, who are provided written informed consent prior to study participation.
Exclusion Criteria
- •1\. Refuse the participation of study
- •2\. \>\= American society of anesthesiologist physical status IV
- •3\. History of diabetes mellitus
- •4\. History of chronic renal failure
- •5\. History of peripheral vascular disease or hyperlipidemia
- •6\. Use of any vasopressor or inotropics for hemodynamic instability before participation of study
- •7\. Inappropriate subjects who are identified by researchers
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2010-018863-40-DEBayer HealthCare AG18
Active, Not Recruiting
N/A
An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatment in subjects with symptomatic pulmonary arterial hypertension - PATENT PLUSPulmonary arterial hypertension.MedDRA version: 9.1Level: LLTClassification code 10064911EUCTR2010-018863-40-ITBayer Health Care AG36
Active, Not Recruiting
N/A
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2010-018863-40-CZBayer HealthCare AG36
Active, Not Recruiting
N/A
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2010-018863-40-PLBayer HealthCare AG36
Active, Not Recruiting
N/A
An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatment in subjects with symptomatic pulmonary arterial hypertension - PATENT PLUSPulmonary arterial hypertensionMedDRA version: 12.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2010-018863-40-ATBayer Health Care AG36